Crystallographic studies on the binding of isonicotinyl-NAD adduct to wild-type and isoniazid resistant 2-trans-enoyl-ACP (CoA) reductase from Mycobacterium tuberculosis

Journal of Structural Biology

Volumn 159, Issue 3, 2007, Pages 369-380

  Dias, Marcio Vinicius Bertacine ^a   Vasconcelos, Igor Bordin ^b   Prado, Adriane Michele Xavier ^a   Fadel, Valmir ^a   Basso, Luiz Augusto ^b   de Azevedo Jr , Walter Filgueira ^b   Santos, Diógenes Santiago ^b  

^a SÃO PAULO STATE UNIVERSITY UNESP   (Brazil)

^b PONTIFICAL CATHOLIC UNIVERSITY OF RIO GRANDE DO SUL   (Brazil)

Author keywords

Crystal structure; Drug resistance; Enoyl ACP reductase; InhA; Isoniazid; Mycobacterium tuberculosis

Indexed keywords

2 ENOYL ACYL CARRIER PROTEIN REDUCTASE (NADH); ENOYL ACYL CARRIER PROTEIN REDUCTASE (NADH); ISONIAZID; NICOTINAMIDE ADENINE DINUCLEOTIDE; UNCLASSIFIED DRUG;

ARTICLE; BACTERIUM ISOLATE; CONTROLLED STUDY; CRYSTALLOGRAPHY; LIGAND BINDING; MISSENSE MUTATION; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; PRIORITY JOURNAL;

BACTERIAL PROTEINS; CRYSTALLOGRAPHY, X-RAY; DRUG RESISTANCE, BACTERIAL; ISONIAZID; MUTATION, MISSENSE; MYCOBACTERIUM TUBERCULOSIS; NAD; NADH, NADPH OXIDOREDUCTASES; OXIDOREDUCTASES; PROTEIN CONFORMATION;

MYCOBACTERIUM TUBERCULOSIS;

EID: 34548335105     PISSN: 10478477     EISSN: 10958657     Source Type: Journal    
DOI: 10.1016/j.jsb.2007.04.009     Document Type: Article

References (46)

1. Banerjee A., Dubnau E., Quémard A., Balasubramanian V., Um K.S., Wilson T., Collins D., de Lisle G., and Jacobs Jr. W.R. inhA, a gene encoding a target for isoniazid and ethionamide in Mycobacterium tuberculosis. Science 263 (1994) 227-230
2. Basso L.A., and Blanchard J.S. Resistance to antitubercular drugs. Adv. Exp. Med. Biol. 456 (1998) 115-144
3. Basso, L.A., Santos, D.S., 2005. Drugs that inhibit mycolic acid biosynthesis in Mycobacterium tuberculosis-an update. Med. Chem. Ver.-online 2, 393-413.
4. Basso L.A., Zheng R., and Blanchard J.S. Kinetics of inactivation of WT and C243S mutant of Mycobacterium tuberculosis enoyl reductase by activated isoniazid. J. Am. Chem. Soc. 118 (1996) 11301-11302
5. Basso L.A., Zheng R., Musser J.M., Jacobs Jr. W.R., and Blanchard J.S. Mechanisms of isoniazid resistance in Mycobacterium tuberculosis: enzymatic characterization of enoyl reductase mutants identified in isoniazid-resistant clinical isolates. J. Infect. Dis. 178 (1998) 769-775
6. Bernstein J.W., Lott A., Steinberg B.A., and Yale H.L. Chemotherapy of experimental tuberculosis. V. Isonicotinic acid hydrazide (nydrazid) and related compounds. Am. Rev. Tuberc. 65 (1952) 357-374
7. Blanchard J.S. Molecular mechanisms of drug resistance in Mycobacterium tuberculosis. Ann. Rev. Biochem. 65 (1996) 215-239
8. CDC (Centers for Disease Control and Prevention), 2006. Emergence of Mycobacterium tuberculosis with extensive resistance to second-line drugs-worldwide, 2000-2004. Morb. Mortal. Wkly. Rep. 55, 301-305.
9. Collaborative Computational Project, Number 4., 1994. The CCP4 suite: programs for protein. Acta Crystallogr. D 50, 760-763.
10. Corbett E.L., Watt C.J., Walker N., Maher D., Williams B.G., Raviglione M.C., and Dye C. The growing burden of tuberculosis: global trends and interactions with the HIV epidemic. Arch. Intern. Med. 163 (2003) 1009-1021
11. DeLano, W.L., 2004. The PyMOL Molecular Graphics System. CA DeLano Scientific.
12. Dessen A., Quémard A., Blanchard J.S., Jacobs Jr. W.R., and Sacchettini J.C. Crystal structure and function of the isoniazid target of Mycobacterium tuberculosis. Science 267 (1995) 1638-1641
13. Espinal M.A. The global situation of MDR-TB. Tuberculosis 83 (2003) 44-51
14. Glickman M.S., and Jacobs Jr. W.R. Microbial pathogenesis of Mycobacterium tuberculosis: dawn of a discipline. Cell 104 (2001) 477-485
15. Guex N., and Peitsch M.C. SWISS-MODEL and the Swiss-PdbViewer: an environment for comparative protein modeling. Electrophoresis 18 (1997) 2714-2723
16. Johnsson K., King D.S., and Schultz P.G. Studies on the mechanism of action of isoniazid and ethionamide in the chemotherapy of tuberculosis. J. Am. Chem. Soc. 117 (1995) 5009-5010
17. Johnsson K., and Schultz P.G. Mechanistic studies of the oxidation of isoniazid by the catalase peroxidase from Mycobacterium tuberculosis. J. Am. Chem. Soc. 116 (1994) 7425-7426
18. Koradi R., Billeter M., and Wüthrich K. MOLMOL: a program for display and analysis of macromolecular structures. J. Mol. Graph. 14 1 (1996) 51-55
19. Kremer L., Dover L.G., Morbidoni H.R., Vilchèze C., Maughan W.N., Baulard A., Tu S.C., Honore N., Deretic V., Sacchettini J.C., Locht C., Jacobs Jr. W.R., and Besra G.S. Inhibition of InhA activity, but not KasA activity, induces formation of a KasA-containing complex in mycobacteria. J. Biol. Chem. 278 (2003) 20547-20554
20. Kuo M.R., Morbidoni H.R., Alland D., Sneddon S.F., Gourlie B.B., Staveski M.M., Leonard M., Gregory J.S., Janjigian A.D., Yee C., Musser J.M., Kreiswirth B., Iwamoto H., Perozzo R., Jacobs Jr. W.R., Sacchettini J.C., and Fidock D.A. Targeting tuberculosis and malaria through inhibition of enoyl reductase: compound activity and structural data. J. Biol. Chem. 278 23 (2003) 20851-20859
21. Larsen M.H., Vilchèze C., Kremer L., Besra G.S., Parsons L., Salfinger M., Heifets L., Hazbon M.H., Alland D., Sacchettini J.C., and Jacobs Jr. W.R. Overexpression of inhA, but not kasA, confers resistance to isoniazid and ethionamide in Mycobacterium smegmatis, M. bovis BCG and M. tuberculosis. Mol. Microbiol. 46 (2002) 453-466
22. Laskowski R.A., MacArthur M.W., Moss D.S., and Thornton J.M. PROCHECK: a program to check the stereochemical quality of protein structures. J. Appl. Crystallogr. 26 (1993) 283-291
23. Lei B., Wei C.-J., and Tu S.-C. Action mechanism of antitubercular isoniazid. J. Biol. Chem. 275 (2000) 2520-2526
24. McRee D.E. XtalView/Xfit-a versatile program for manipulating atomic coordinates and electron density. J. Struct. Biol. 125 (1999) 156-165
25. Middlebrook G., and Cohn M.L. Some observations on the pathogenicity of isoniazid-resistant variants of tubercle bacilli. Science 118 (1953) 297-299
26. Mitchison D.A. The action of antituberculosis drugs in short-course chemotherapy. Tubercle 66 (1985) 219-225
27. Morlock G.P., Metchock B., Sikes D., Crawford J.T., and Cooksey R.C. ethA, inhA, and katG loci of ethionamide-resistant clinical Mycobacterium tuberculosis isolates. Antimicrob. Agents Chemother 47 (2003) 3799-3805
28. Murshudov G.N., Vagin A.A., and Dodson E.J. Refinement of macromolecular structures by the maximum-likelihood method. Acta Crystallogr. D 53 (1997) 240-255
29. Navaza J. AMoRe: an automated package for molecular replacement. Acta Crystallogr. A 50 (1994) 157-163
30. Anon, 2006. Addressing the threat of tuberculosis caused by extensively drug-resistant Mycobacterium tuberculosis. Wkly. Epidemiol. Rec. 21, 386-390.
31. Oliveira J.S., Pereira J.H., Canduri F., Rodrigues N.C., de Souza O.N., de Azevedo Jr. W.F., Basso L.A., and Santos D.S. Crystallographic and pre-steady-state kinetics studies on binding of NADH to wild-type and isoniazid-resistant enoyl-ACP(CoA) reductase enzymes from Mycobacterium tuberculosis. J. Mol. Biol. 359 3 (2006) 646-666
32. Oliveira J.S., Vasconcelos I.B., Moreira I.S., Santos D.S., and Basso L.A. Enoyl reductases as targets for the development of anti-tubercular and antimalarial agents. Curr. Drug Targets 8 3 (2007) 399-411
33. Ormerod L.P. Multidrug-resistant tuberculosis (MDR-TB): epidemiology, prevention and treatment. Br. Med. Bull. 73-74 1 (2005) 17-24
34. Pablos-Mendez A., Gowda D.K., and Frieden T.R. Controlling multidrug-resistant tuberculosis and access to expensive drugs: a rational framework. Bull. World Health Organ. 80 (2002) 489-495
35. Parikh S., Moynihan D.P., Xiao G., and Tonge P.J. Roles of tyrosine 158 and lysine 165 in the catalytic mechanism of InhA, the enoyl-ACP reductase from Mycobacterium tuberculosis. Biochemistry 38 (1999) 13623-13634
36. Polikarpov I., Perles L.A., de Oliveira R.T., Oliva G., Castellano E.E., Garratt R.C., and Craievich A. Set-up and experimental parameters of the protein crystallography beam line at the Brazilian National Synchrotron Laboratory. J. Synchrotron Radiat. 5 (1998) 72-76
37. Quémard A., Sacchettini J.C., Dessen A., Vilcheze C., Bittman R., Jacobs Jr. W.R., and Blanchard J.S. Enzymatic characterization of the target for isoniazid in Mycobacterium tuberculosis. Biochemistry 34 (1995) 8235-8241
38. Rawat R., Whitty A., and Tonge P. The isoniazid-NAD adduct is a slow, tight-binding inhibitor of InhA, the Mycobacterium tuberculosis enoyl reductase: adduct affinity and drug resistance. Proc. Natl. Acad. Sci. USA 100 (2003) 13881-13886
39. Rozwarski D.A., Grant G.A., Barton D.H.R., Jacobs W.R., and Sacchettini J.C. Modification of the NADH of the isoniazid target (InhA) from Mycobacterium tuberculosis. Science 279 (1998) 98-102
40. + and a C16 fatty acyl substrate. J. Biol. Chem. 274 22 (1999) 15582-15589
41. Schroeder E.K., de Souza O.N., Santos D.S., Blanchard J.S., and Basso L.A. Drugs that inhibit mycolic acid biosynthesis in Mycobacterium tuberculosis. Curr. Pharm. Biotechnol. 3 (2002) 197-225
42. Uchoa H.B., Jorge G.E., Freitas Da Silveira N.J., Camera Jr. J.C., Canduri F., and De Azevedo Jr. W.F. Biochem. Biophys. Res. Commun. 325 (2004) 1481-1486
43. Veyron-Churlet R., Guerrini O., Mourey L., Daffe M., and Zerbib D. Protein-protein interactions within the fatty acid synthase-II system of Mycobacterium tuberculosis are essential for mycobacterial viability. Mol. Microbiol. 54 (2004) 1161-1172
44. Vilchèze C., Wang F., Arai M., Hazbon M.H., Colangeli R., Kremer L., Weisbrod T.R., Alland D., Sacchettini J.C., and Jacobs Jr. W.R. Transfer of a point mutation in Mycobacterium tuberculosis inhA resolves the target of isoniazid. Nat. Med. 12 (2006) 1027-1029
45. + ratio mediates coresistance to isoniazid and ethionamide in mycobacteria. Antimicrob. Agents Chemother. 49 (2005) 708-720
46. Zabinski R.F., and Blanchard J.S. The requirement for manganese and oxygen in the isoniazid-dependent inactivation of Mycobacterium tuberculosis enoyl reductase. J. Am. Soc. Chem. 119 (1997) 2331-2332